

29 August 2017

OBJ's First Pharmaceutical Clinical Study Commences

OBJ Limited (ASX: OBJ) is pleased to announce that the clinical efficacy study into the enhanced transdermal delivery of Ibuprofen ("IBU") versus a placebo will commence today after receiving Ethics Committee approval.

The study is expected to run over a three-month period at Curtin University's School of Physiotherapy.

OBJ's interest in clinically testing its microarray hydrogel hybrid technology, initially developed for the BodyGuard project, was encouraged by a major US pharmaceutical manufacturer ("Manufacturer") of IBU treatments for consumer pain management. The Manufacturer does not currently have a topical analgesic product and is interested in the enhanced performance possibilities the OBJ technology has the potential to deliver.

With technical support and protocol advice from the Manufacturer, the OBJ pre-clinical team developed a new microarray hydrogel hybrid patch product that in laboratory studies showed encouraging levels of IBU delivery. It also appears capable of meeting the necessary IBU tissue concentrations required for success.

The relationship with the Manufacturer is being managed by OBJ's USA-based pharmaceutical consultant Dr Steve Mellor, who has extensive experience in IBU clinical studies and a longstanding relationship with the Manufacturer's analgesic team.

The clinical study and production of the IBU patch products is being financially supported on a dollar for dollar basis by the Commonwealth Government under the Innovation Connections Grant Scheme.

The study is expected to serve three primary purposes:

- To demonstrate the ability of OBJ's microarray hydrogel hybrid platform to provide effective transdermal delivery of a wide range of pharmaceutical ingredients that are not well served by current drug-in-adhesive patch technologies
- To further strengthen OBJ's marketing and partnering position with pharmaceutical companies seeking to avoid the common adverse side effects of oral non-steroidal anti-inflammatory drugs (NSAIDs)
- To provide clinical data support for regularity submission should OBJ decide to develop its own propriety IBU patch product platform

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk
Mr Steven Schapera

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

29 August 2017

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

Forward-Looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420